Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Learn more

.

Actinium-225

Explore the potential of Actinium-225, a synthetic isotope with a crucial role in Targeted Alpha Therapy for cancer treatment.

Actineer Inc. is a new joint venture for industrial scale production of Actinium-225

Actineer Inc. was founded in 2023 by ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL), which manages and operates the national laboratory at Chalk River, Ontario, on behalf of Atomic Energy of Canada Limited (AECL).

As a rare alpha emitting medical isotope, Ac-225 is gaining increasing attention across the precision oncology field due to its significant potential as a powerful new potential weapon in the fight against cancer.

Plenty of radiopharmaceutical companies included Ac-225-based molecules as lead program to their pipeline already being well advanced in some cases and requiring this radioisotope as starting material on-time in-full.

The joint venture’s overall goal is to fulfill the unmet global needs of Actinium-225 in order to ensure a reliable supply urgently needed for next generation radiopharmaceuticals and patients worldwide.

.

Latest News

May 15th, 2025

CNL awarded for production of Ac-225 for Actineer

Canadian Nuclear Isotope Council honours CNL, Sylvia Fedoruk Centre and Advanced Cyclotron Systems for first cyclotron irradiation of...

Learn more
January 16th, 2025

Actineer Appoints New President and CEO

Actineer, a joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., today announced the appointment of Joseph...

Learn more
October 17th, 2024

Actineer Advances
Ac-225 Production

Chalk River, Ontario, October 17, 2024 – Actineer, the joint venture between ITM and Canadian Nuclear Laboratories (CNL) Ltd., has...

Learn more
December 7th, 2023

Actinium-225 production

Toronto – December 7 2023 – In support of Canadian Nuclear Isotope Council’s (CNIC) goal of ensuring a reliable supply of medical...

Learn more
October 18th, 2023

ITM and CNL Announce the Launch of Actineer

ITM Isotope Technologies Munich SE (ITM), a leading radio- pharmaceutical biotech company, and Canadian Nuclear Laboratories (CNL)

Learn more

Mission

We strive everyday to produce and deliver the highest quality radioisotopes, to be a reliable and robust partner so that everyone who needs our highest specification medical isotopes can access the care that they need.

.

Actineer Quotes

.

Actinium-225 is a potent radionuclide utilized in targeted alpha therapies and holds great potential in the greater landscape of radionuclide therapy. Targeted alpha therapy with Actinium-225 will facilitate patient care in nuclear medicine by bringing new treatment opportunities to those who need it in addition to combining Radiopharmaceutical therapy possibilities with the established Lutetium-177. The expertise that ITM and CNL bring together is unique and essential for meeting the escalating demand for Actinium-225 across various applications.

Dr. Sebastian Marx,
CBO of ITM
.

Targeted alpha therapies based on Actinium-225 are gaining increasing importance in addition to the well-established beta emitters such as our highly-pure non-carrier-added (n.c.a.) Lutetium-177. Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide.

Steffen Schuster,
Vice Chairman of the Board of ITM
.

It is our role to drive nuclear innovation in Canada, to bring private and public expertise together to spark these new initiatives that will ultimately benefit the health of Canadians and bring new jobs to Canada. We are building on decades of Canada’s world-leading isotope innovation, and have found the key to success is collaboration, partnership, and strong leadership. We are pleased to support the joint venture between CNL and ITM with shared values to bring this potentially lifesaving therapy to the world.

Fred Dermarkar,
President and CEO of AECL
.

Actineer, the joint venture between ITM and CNL, is addressing the growing and urgent global demand for Actinium-225—a rare medical radioisotope that enables the development of innovative therapies for hard-to-treat tumors. By ensuring a stable, scalable supply of this critical resource, Actineer helps to advance both clinical trials and the development of potential life-saving treatments for cancer patients worldwide.

Dr. Andrew Cavey,
CEO of ITM
.

Our joint venture Actineer has been launched with the overall goal to ensure access to Ac-225 as a next generation radioisotope through an innovative technology.
With the foundation of Actineer we have committed us to establish a reliable, long term and substantial production of Ac-225 in high quality standards.
This Canada based company will facilitate ground breaking research activities leading to novel cancer treatments urgently needed by many patients worldwide.

Dr. Andreas Benischke,
VP Global Actinium Lead of ITM
.

Actineer is poised to become one of the major global suppliers of Actinium-225. I am privileged to work with such premier institutions as CNL and ITM and am eager to leverage my expertise and work together with the Actineer team to achieve this goal and thereby support the development of innovative targeted alpha radiopharmaceuticals for the treatment of challenging cancer indications.

Joseph Oliverio,
President and CEO

Current Partnerships

ITM
SFCCNI
CNL
CNIC
USask
ACSI